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Therapeutic options to treat mustard gas poisoning – Review 
 
Abstract 
Among the blistering (vesicant) chemical warfare agents (CWA), sulfur mustard is the 
most important since it is known as the “King of chemical warfare agents”. The use of 
sulfur mustard has caused serious damages in several organs, especially the eyes, skin, 
respiratory, central and peripheral nervous systems after short and long term exposure, 
incapacitating and even killing people and troops. In this review, chemical properties, 
mechanism of actions and their effects on each organ, clinical manifestations, diagnostic 
evaluation of the actions triage, and treatment of injuries have been described. 
Keywords: Sulfur mustard, Mustard gas, Blistering (vesicant) agents, Bronchopneumonia, 
Chronic obstructive pulmonary disease. 
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Over a few decades ago till now, due to abundant availability of various chemicals, 
the rate of intoxication has surprisingly increased (1, 2). People can overuse or misuse 
some chemicals, and get poisoned intentionally or accidentally (3, 4). An important point 
to pose is that chemical agents continue to be a concern used by terroristic organizations, 
and local- regional wars. These agents have seriously caused short and long-term damages, 
kill, or incapacitate ordinary and military persons in urban and war fields (5). The first 
reports of the use of chemical warfare agents have been found in ancient Greek and Roman 
writings. The modern uses of the agents have been reported during World War I (WWI).  
The Geneva Protocol in 1925 was the first major international effort to limit development, 
and subsequently use these agents during World War II(WW II), as well as their frequent 
use up to now (5, 6). Among the mass destruction weapons, chemical warfare is one of the 
most brutal created by mankind. In the last decades, modern chemical warfare agents have 
been repeatedly used in various classes with different chemical properties. They cause 
toxic and lethal effects and extensive human suffering (7). Blistering (vesicant) agents are 
important substances of CWAs. Sulfur mustard (mustard gas or “king of CWAs”), 
nitrogen mustards (HN1, HN2, and NH3) and lewisites (L1, L2, and L3) are the major 
categories of blister agents (8). The most commonly used chemical warfare agent is sulfur 
mustard (mustard gas). Other names are yperite (Y pres was the place of the first military 
use), LOST (the first family name of the German chemists’ Lommel and Steinkopf 
investigated the military use), and yellow cross (German shells were marked with a yellow 
cross due to skin damage (9). Sulfur mustard (SM) was first used on the battlefield near 
Ypres, Belgium on July 12, 1917 by German military forces. It was responsible for more 
than 80% of the recorded chemical warfare injuries. In December 1943, an allied ship 
carried a large amount of mustard gas and exploded in Bari harbor, Italy. It has been used 
sporadically since World War I (10), but the last military use was during Iran- Iraq war 
(1980-1988), specially occupied the village of Halbja in 1988 by Iraq chemical attack, 
wherein over 100000  of people and soldiers were injured and one- third of them have 
been suffering from its late effects so far(9, 11, 12). 
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■ Physico-chemical properties 
Pure sulfur mustard [C2H4Cl2S] is a colorless and 
odorless liquid, but because the impure substance has smell 
similar to mustard or garlic. It is easily soluble in organic 
solvents and slightly in water (8). Some of physicochemical 
properties of sulfur mustard include; molecular weight: 
159.08, density: 1.27 (specific gravity), solubility: very 
hydrophobic, freezing point: 14.45 °C, boiling point 215-217 
°C (9). It has strongly alkylating, nucleophilic, lipophilic, 
cytotoxic, mutagenic and carcinogenic properties. It is 
known as the “king of the battle gases (5, 13). 
■ Mechanism of action 
A few theories explained the mechanism of action of 
sulfur mustard. The first was about the acid liberation theory; 
in which sulfur mustard becomes hydrolyzed within cells as 
hydrochloric acid. This theory was not soon accepted 
because vesicant action cannot act along with the amount 
released acid (9). Another theory was reactions of sulfur 
mustard with proteins and several enzymes that were 
inhibited, specially hexokinase. It is important that the level 
of alkylation needed for in vitro inhibition of these enzymes 
is not enough at vesicant doses in vivo. In addition, 
hexokinase may have inhibited alkylation after a few 
minutes. But, sulfur mustard appears to induce tissue damage 
with a noticeable delay in vitro and in vivo. Therefore, this 
theory may be rejected (9, 14, 15). Another theory suggests 
that sulfur mustard may deplete glutathione storage and lipid 
peroxidation. On the other hand, the sulfhydryl groups in 
proteins and other compounds containing glutathione can 
quickly deactivate lipid peroxidation processes. These 
compounds maintained the suitable oxidation- reduction 
reactions in cells. In fact, glutathione reduces reaction 
oxygen species in cell, also prevents peroxidative processes. 
When cells are exposed to sulfur mustard, depletion of 
glutathione and then lipid peroxidation occur. All the above 
mentioned theories are not in agreement with delay damage 
after sulfur mustard exposure. However, some of these 
theories justify and recognize sulfur mustard cytotoxicity (9, 
11). The most important theory is alkylation of cell parts by 
sulfur mustard. That means alkylation reactions in affected 
cells, mainly are responsible of injuries of DNA, RNA, 
protein, lipid membranes. Mustard spontaneously undergoes 
intramolecular cyclization. This cyclization causes to 
eliminate chloride ion forming ethylene sulfonium ring. 
Reactive sulfonium ion alkylates sulfhydryl (-SH) and amino 
(-NH2) groups. That makes this point an indirect inhibition 
of glycolysis (16).The ethylene sulfonium in the middle of 
the process is converted to carbonium ion, and reacts 
immediately with DNA, RNA, protein and other molecules 
(9). At last, sulfur mustard reacts with DNA, which is the 
result of the N7 position of guanine [7- (2-
hydroxyethylthioethyl)] guanine (7-HETE-G) (61%), N1 
position of adenine, N3 position of adenine (16%) and O6 
position of guanine (0.1%) (17, 18). The above description is 
a summary of the DNA alkalization. This process is achieved 
as single-and-double-strand DNA breaks. Then, cells try to 
repair the damaged DNA. This leads to activations of poly 
(ADP-ribose) polymerase (PARP) (19). Two classes are 
presented PARP-1 and PARP-2 in activated by DNA strand 
breaks. PARP-1 is a first line protein encountered in the 
cellular response to DNA strand breaks. The biological 
activity of PARP-1 causes to maintain survival and cell 
integrity undergoing genotoxic stress (20). But excessive 
PARP activity may cause to the cellular depletion of 
nicotinamide adenine dinucleotide (NAD
+
), also, 
simultaneous reduction of glycolysis (15). NAD
+ 
depletion 
and glycolysis inhibition lead to impairing energy production 
in the cell. As a result, ATP loss causes cell death (17) 
(Fig1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1- Scheme in relation to damaging various systems 
via mustard poisoning.  
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Mustard gas changes in the different parts of the cell. 
DNA alkalization and DNA breakdown cause oxidative 
stress and protein and lipid peroxidation. This agent 
maintained the reduction- oxidation in the cellular of the 
organs. With the decrease in glutathione followed by an 
increase in ROS, resulted to subsequent creation of different 
processes of damage to various organs. 
■ Clinical Manifestation 
● General 
The first exposure to sulfur mustard is often without pain. 
People smell only a little garlic or sulfur odor. Naturally, 
symptoms will be shown for several hours. The maximum 
severity of symptoms appears after a few days. The most 
affected organs by contact with sulfur mustard (mustard gas) 
are eyes, skin and respiratory system (9, 16). It should be 
noted, that if sulfur mustard is distributed in the air of the 
places like battlefield, can hurt eyes, skin, and respiratory 
system. Although, the intensity of injury depends on the 
dose, route of exposure, protection method, environmental 
conditions (e.g., temperature and humidity), demographic 
parameters of the victims (e.g., age, sex, height) etc. (15). 
The time to start of signs and symptoms is as follows; 
nausea, vomiting, eye pain in 30-60 minutes, lacrimation, 
photophobia, rhinorrhea, sneezing, and sore throat in 2-6 
hours, erythema, hoarseness, non-productive cough in 6-24 
hours, skin blistering, productive cough in 24-48 hours, 
ocular recovery starts, hyperpigmentation, secondary 
infections in 2-6 days(21). The lethal oral dose for humans is 
200 mg. The amount of 4-5 gr on naked skin in a long 
exposure time and 1500 mg/min/m
3
 via respiratory system 
may be the lethal dosage of sulfur mustard(22). 
● Eyes  
The most sensitive organs during exposure to sulfur 
mustard are eyes. The dose threshold of toxicity of sulfur 
mustard for eyes and skin are 12 mg min/m3and 200mg/min/m
3
, 
respectively. Even low doses provide incapacitation and 
visual impairment (23, 24). After an hour of exposure to 
sulfur mustard, symptoms start with a sensation of grittiness, 
advance soreness, and bloodshot eyes before edema and 
acute conjunctivitis. When concentrations are less than 50 
mg/min/m
3
, simple conjunctivitis and corneal swelling may 
appear, and edema occurs when the dose is higher than 200 
mg min/m
3
(23, 25). During the 2-6 hour after exposure, 
patients feel severe ocular pain, laceration, photophobia, 
blepharospasm, and reduced visual acuity, also temporary 
blindness after 1 to 12 hours. Usually spontaneous recovery 
happens after 48 hours, with full regeneration of the corneal 
epithelium occurring on day 4 to 5, however complete 
recovery may take 6 weeks or more(22, 23, 26). But the 
findings are delayed and more severe phase leads to 
irreversible visual impairments and even blindness (this 
point is controversial). Based on the animal studies (a few 
weeks) and investigation on human victims (several years), 
there is a chemical silent period in epithelial corneal defects 
and corneal neovascularization (NV), thinning and opacity 
(24, 27). Severe lesions may be associated by a low grade 
iridocyclitis without synechia or cataract formation, also 
intraocular pressure (IOP) may transiently increase for a few 
days (23, 28, 29). War victims suffered chronic or delayed- 
onset mustard gas keratitis (MGK) (30). Generally, the 
victims with MGK usually suffer chronic keratitis, impaired 
corneal sensation, recurrent/ persistent corneal erosions, 
limbal stem cell deficiency (LSCD) , corneal neovascularization, 
lipid and amyloid deposition, irregularity, and corneal 
thinning and scarring (15, 23). Limbal stem cell deficiency 
can be mild to moderate. LSCD may cuse distructive loss of 
limbal epithelial stem cells, or dysfunctional limbal stroma 
(31). Patterns of eye injuries are posed after exposure to 
sulfur mustard with the present dose in mg per minute in 
cubic meter and time duration in table 1.  
● Respiratory 
After ophthalmologic lesions of sulfur mustard exposure, 
respiratory symptoms are seen. These complications happen 
before skin lesions appear (33). Upper and lower respiratory 
system may be affected by sulfur mustard.(34). While sulfur 
mustard is being inhaled as spray, mostly the larynx, 
pharynx and tracheobronchial mucosa are affected. The 
symptoms appear in the upper respiratory system with pain 
and discomfort in the nose or sinus, next irritation of nasal 
mucosa, hoarseness, sneezing and coughing. When exactly 
developed, symptoms can range from, lacrimation, from not 
being able to smell or taste, loss of smell and taste, and 
discharge of mucosal secretions from nose and throat (25, 
35). Large volumes of vapor will cause laryngeal injury 
(aphonia and husky voice and upper medium-sized airway 
damage (tracheobronchitis) that nonproductive hacking 
cough usually reveal. The gas in higher concentration can 
reach into lower parts of the airways and may result in 
persistent cough, dyspnea, and likely hemorrhage into the 
alveoli. Finally, the adult respiratory distress syndrome may 
occur (25). Infection of respiratory system is a common 
complication after 36-48 hours. Prolonged recovery after 1 
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to 2 months may occur, especially following secondary infections and necrotic bronchopneumonia(22). 
Table1. Patterns of ocular damage as a result of sulfur mustard exposure (22, 32) 
Ocular disorders 
 
Phase Severity Dose in 
mg/min/m3 
(environment 
air) 
Duration 
Symptoms Signs   
Foreign body sensation, 
tearing, photophobia, 
blepharospasm, 
Eyelids hyperemia, vascular dilation and hyperemia of the 
conjuctive,  
Acute Mild 12-70 
( In some cases, 
more than 100 
to 200) 
Up to 2 
weeks 
 Same as mild damage, 
dry eye sensation, eye 
pain 
Same as mild damage, 
conjunctival edema, corneal epithelial edema, corneal 
epithelial erosion, superficial punctuate keratopathy (more 
in the lid fissure area) 
 Moderate 
Same as mild and 
moderate, severe ocular 
pain, swelling, redness, 
sores and spasms of the 
eyelids, reduced vision 
Same as mild and moderate, inflammation, edema and in 
some cases, secondary infection of the conjunctive, 
ischemia and necrosis of the conjunctive, limbal ischemia 
and necrosis, corneal epithelial irregularity and defect, 
corneal stromal edema, possible corneal infection, 
inflammation of the anterior chamber (uveitis), perforation 
of the cornea 
 Severe 
Photophobia, burning, 
foreign body sensation 
in eyes, dry eye, tearing, 
slight redness of the eye 
Meibomian gland dysfunction, chronic blepharitis, reduced 
thickness of the tear meniscus layer, telangiectasia of the 
conjunctival blood vessels, comma shape vascular 
tortuosity in the palpebral fissure area (nasal and temporal), 
subjunctival fibrosis, subconjunctival hemorrage, scarring 
of the conjunctiva, punctuate epithelia erosions 
Chronic 
and 
delayed 
Mild 100-200 
( In some cases, 
more than 200) 
3-6 
weeks 
   
Same as mild damage, 
reduced vision, marked 
red eye, itchy eyes, 
ocular pain 
Same as mild damage, corneal irregular astigmatism, 
periods of relapse and remission, mild to moderate limbal 
ischemia, irregular cornea, thinning of corneal periphery, 
corneal opacity as well as lipid and amyloid material and 
deposition in the corneal periphery, peripheral corneal 
vascularization, peripheral stromal scars of the cornea, 
peripheral intra-corneal hemorrhage, transparency of the 
corneal center, decreased corneal sensation 
 Moderate 
Same as mild and 
moderate, severe 
photophobia, severe 
vision loss, severe pain 
Same as mild and moderate, severe limbal ischemia, limbal 
cell deficiency, thinning and opacity of the central and 
peripheral parts of the cornea, corneal opacity as well as 
lipid and amyloid deposition in the cornea, central and 
peripheral corneal vascularization, band keratopathy and 
scars in the central and  
peripheral corneal stroma,central and peripheral intra-
corneal hemorrhage, corneal conjunctivalization, corneal 
descemetocele, corneal ulcer, corneal melting and 
perforation, history of limbal and corneal surgeries 
 Severe 
Permanent blindness    > 200 Very rare 
 
The important complaints of the late finding of upper 
respiratory tract in sulfur mustard poisoning include 
shortness of breath, cough and sputum, intermittent and  
 
continuous dysphonia. Laryngoscopic recording expressed  
inflammation (edema and erythema) in supraglottic and 
subglottic regions. In general, patients suffered chronic 
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laryngitis. Also, synechia and nodules may have been caused 
by infectious or chronic laryngobronchitis (36). Chest x-ray 
assessments of lower respiratory tract indicate obstructive 
lung disease, hyperinflation, air trapping, increased marking 
around the bronchioles, and bronchiectasis. In addition, 
pulmonary function test (PFT) shows decreased forced 
expiratory volume in one second (FEV1), forced vital 
capacity (FVC), and the ratio between these two volumes 
(FEV1/ FVC) is an indication of obstructive pattern (37). The 
involvement of pulmonary lesions by spirometry and 
severity (mild, moderate, severe, respectively) are as 
follows; 65≤FEV1<80 or 65≤FVC<80 (mild), 50≤FEV1<65 
or 50≤FVC<65 (moderate), 40≤FEV1<50 or 40≤FVC<50 
(severe)(37). Exposure to sulfur mustard can cause cancer of 
the upper respiratory system, also some evidence shows that 
it can result to lung cancer (38). 
Generally, respiratory sequelae includes chronic 
bronchitis, emphysema, tracheobronchomalacia, and 
bronchiolitis obliterans(16). Several studies confirmed that 
chronic bronchitis is   common late complication by 
exposure to sulfur mustard in the lower respiratory tract. 
However, the presence of hypoxemia and hypercapnia from 
asthmatic bronchitis leads to chronic obstructive pulmonary 
disease (COPD), cor pulmonale, and respiratory failure in 
the end stages of the disease (33, 39, 40). High- resolution 
computed tomography (HRCT) technique confirmed air 
trapping, bronchiectasis with dyspnea, productive cough and 
hemoptysis, pleural thickening with hemoptysis and chronic 
bronchitis (41, 42). 
● Skin 
Skin is an important vulnerable tissue to sulfur mustard. 
Various factors such as temperature, humidity and 
anatomical position determine the type of injuries and 
intensity of symptoms. Sulfur mustard reacts with skin 
proteins and degrades the cell`s proteins and underlying 
extracellular matrix (35, 43). After exposure, the cutaneous 
effects start from 2 to 24 hours. The first signs and 
symptoms include erythema, skin lesions with or without 
blister formation, itching and burning sensation that could be 
seen. Also, large flaccid bullae may progress, then unify, 
following slough like large sheets of epithelium (Nikolsky’s 
sign). If large areas are involved with disturbance of water 
and electrolyte, secondary infection may occur (21, 26, 44, 
45). They are usually localized in warm moist areas such as 
the groin and axilla. Lesions tend to heal slowly, and it 
frequently causes wounds and blisters (43). Blisters start 
with small vesicles within erythema. They gradually unify to 
pendulous blisters with large volumes of clear yellow 
fluid(25).Hyperpigmentation usually follows after erythema. 
When melanocyte destruction occurs there will be 
hypopigmentation(44).   
Acute sulfur mustard exposure on human skin depends 
on dose and its dosage form; itching, dry and pale of the 
exposed area (vapor:50-100 mg/min/ m
3
, liquid: 10-20 
µg/cm
2
) (46),  erythema can often be observed at a threshold 
dose (vapor: 100-300 mg /min/m
3
, liquid: 10-20 µg/cm
2
) , 
blister formation occurs at higher doses (vapor: 1000-2000 
mg /min/ m
3
, liquid: 40-100 µg/cm
2
) (35). Also, in 50% of 
people exposed to sulfur mustard in skin with vapor ~ 10,000 
mg /min/m
3
, and liquid 100 mg/kg resulted in death (27, 46). 
But chronic and delay complications of the skin caused 
by exposed to sulfur mustard depends on the incidence and 
insistence of lesions following sulfur mustard exposure. It is 
directly related to time and intensity of exposure (22). As 
mentioned, about 80% of the sulfur mustard in contact with 
skin evaporates, and only 20% of the remaining penetrate 
into the tissue, namely keratinocytes and hair follicle cell 
membrane. It cannot be removed in ten minutes, and will 
bind to the epidermal and dermal tissue, often in the 
cornified layer (47, 48).  
In most studies, the patient’s complaint of itching 
followed burning sensation and desquamation, due to 
dryness of the skin, especially in dry weather and physical 
activity. Axilla, scrotum, and anal region have high humidity 
and sensitivity to the exposure (49). Sulfur mustard vapor 
results in 1
st
 or 2
nd
 degree burns, and its liquid in full 
thickness burns, because it easily penetrates normal military 
uniforms. Therefore, it causes gluteal, perineal, and scrotal 
burns. Mild burns usually heal spontaneously and with 
ordinary care. However, deep burns are a candidate for skin 
graft (16, 48). 
Other complications noted in late skin lesions are 
excessive dry skin (xerosis), itching, hyperpigmentation and 
hypopigmentation, local hair loss, eczema, chronic urticarial, 
and  cherry angioma (25, 33, 47). When blister erupted, a 
necrotic layer or eschar is formed on the skin. The wounds 
usually heal over the period of 10-50 days, pigmentary 
changes may persistently remained for months or years(19). 
Pigmentation can decrease or increase in function at late skin 
disorder in the location of primary sulfur mustard lesions. If 
melanocytes are healthy, hyperpigmentation occur. 
However, the effects of sulfur mustard on the pigmentation 
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can appear as hypopigmentation. In the case of melanocytes 
are destruction, depigmentation well be diagnosed (25, 37, 
50). Another point is the appearance of cherry angioma and 
telengiectasis, which is seen in patients exposed to sulfur 
mustard. Cherry angioma is a benign vascular neoplasm 
(50).  
● Mutagenicity, Teratogenicity, and Carcinogenicity 
There is no evidence for the mutagenicity of sulfur 
mustard and no document of teratogenicity was found in rats 
with different doses of sulfur mustard (51).Sulfur mustard is 
an alkylating agent that affects DNA. It may induce long-
term cancer  after exposure (52).Sulfur mustard is classified 
as a carcinogen by the international agency for research on 
cancer (IARC).Human studies indicate an association 
between occupational or battlefield exposure to sulfur 
mustard and induce respiratory, skin, gastric cancers. There 
are many reports of leukaemia and upper respiratory tract 
malignancies in old Japanese, British and American workers 
of factories that manufacture sulfur mustard. Lung cancer, 
nasopharanx and bronchogenic carcinoma, adenocarcinoma 
of stomach, as well as acute myeloblastic and lymphoblastic 
leukaemia have neen reported among the Iranian veterans 
(21, 22, 51, 52). 
●Hematopoietic andimmune and systems 
Leukocytosis is usual in the first few days after sulfur 
mustard exposure. White blood cells (WBCs) count begin to 
decline on the 3
rd
 and 4
th
 days after exposure and reach their 
minimum level around the 9
th
 day. Lymphocytes are the first 
line to disappear and granulocytes are also strictly affected 
but they are reduced with delay after lymphocytes (51). 
Leukopenia reaches a lowest count about 10 the day after the 
exposure (21). Thrombocytopenia and anemia appear later 
(53). Bone marrow biopsy demonstrates a decrease in cell 
numbers and cellular atrophy. High dose exposure induces a 
cytotoxic effect in hematopoietic stem cell leading to 
pancytopenia (53). 
Immune responses are categorized into two types:  
humoral, which is intervened by antibodies and cellular 
which is mediated by T cells (54). Sulfur mustard poisoning 
can impair both humoral and cellular immune functions (51). 
Sulfur mustard may increase the levels of IgG and IgM 
during the first week, but their levels decrease over the next 
6 months (55, 56). Sulfur mustard is also effective on 
complement system (57). Complement changes are likely 
related to the acute phase response following infections, and 
may indicate the efficiency of the classic pathway in the 
complement system (58). Both C3 and C4 levels increase, 
then a gradual decrease is seen over one year, remaining up 
to three years after exposure, specifically in patients with 
severe poisoning (51). T helper cells remarkably decreased 
while  T suppressors increased in patients exposed to sulfur 
mustard(58). Also, check out on CD45 (common leukocyte 
antigen present on 99% of leukocytes), CD56 (natural killer 
(NK) cell marker present on 70% of NK cells) and CD25 
(interleukin2 R (IL) present on activated NK cells) marker 
(54, 57). Most studies revealed that there is a probability of 
impairment in cellular immunity especially NK cells by 
sulfur mustard. In people exposed to sulfur mustard there are 
risks of cancer and also recurrent fungal and viral 
infections(57). In addition, the assessment of the ratio of 
CD45+ /CD56+ cells,  CD56+ /CD25+  cells, CD8+ / CD56+ cells 
that are importantly lower, and noticeably higher, within the 
normal range in severe patients exposed to sulfur mustard 
was compared with the control group, respectively(54). 
● Endocrine and Reproductive systems 
Azizi et al. (2001) reported the effect of sulfur mustard 
on endocrine systems and showed a decrease of thyroid 
hormones and an increase in reverse T3 (rT3). The following 
has reported an increase in adrenocorticotropic hormone 
(ACTH) during first week after exposure, increase in free 
plasma thyroxine index (FT4I), a thyroid stimulating 
hormone (TSH) after three weeks of exposure, a continuous 
increase of ACTH up to  week 5, and a significant reduction 
in cortisol in weeks 4 and 5  after sulfur mustard 
poisoning(59). Safarinejad (2001) found that the total and 
free testosterone and dehydroepiandrosterone (DHEA) levels 
noticeably decreased in the first 5 weeks after exposure. 
Follic- stimulating hormone (FSH), luteinizing homone 
(LH), prolactin, and 17 alpha-OH progesterone were normal 
in the first week. LH increased in the third week while FSH 
and prolactin increased in the fifth week. All hormone levels 
returned to normal in the twelfth week after exposure (60). 
Marzony et al. (2016) reported that sulfur mustard caused 
wide changes of structural and functional defects in 
reproductive system including disturbances in the levels of 
reproductive hormones, testicular damages, sexual 
dysfunction, genital lesions, impaired spermatogenesis, poor 
sperm quality (count, motility, morphology, viscosity, 
volume) and reduced fertility(61).Several studies on 
testicular biopsies revealed partial or complete stop of 
spermatogenesis, atrophy of the germinal epithelium, intact 
Sertoli cells, and normal appearance of Leydig cells (60, 61). 
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● Other Systems 
Gastrointestinal (GI) tract could be affected following 
sulfur mustard exposure. The most common GI symptoms 
are as follows: nausea, vomiting, anorexia, abdominal pain 
and diarrhea in the first 24 hours. In some victims, acute 
gastroduodenitis with hemorrhagic erosions, acute 
desquamative enteritis, and severe hemorrhagic necrotic 
colitis have been reported (22, 51). Pancreatic autopsy 
findings were chronic inflammation, fibrosis, duct ectasia 
and acinar atrophy (62). 
Convulsion, dizziness, anorexia, vomiting, and increased 
cholinergic activity may be observed following central 
nervous system acute toxicity of sulfur mustard. Chronic 
toxicity includes debility, decreased vitality, attention deficit, 
increased sensibility, impotence, and cardiac autonomic 
abnormalities (63). Headache, anxiety, fear of the future, 
restlessness, confusion, and lethargy are seen in mild and 
nonspecific neurological manifestations (11). Delayed 
neuropathic disorders were seen in peripheral nervous 
system (11, 51). Some victims had pure sensory 
polyneuropathy and the other had sensory-motor distal 
polyneuropathy of axonal type. Sensory nerve impairments 
comprise hyperesthesia, hypoesthesia (sign), and 
paraesthesia (symptom) that were the most ordinary clinical 
complications (64).  
Balali-Mood et al. (2005) reported abnormalities in the 
peripheral nervous system as results of electromyography 
(EMG) and nerve conduction velocity (NCV) Iranian 
veterans.  They showed sensory nerve disorders more than 
motor nervous disorders, as well as, the prevalence of these 
problems were in lower extremities more than the upper 
extremities. EMG was normal in some patients, whereas in 
the other patients had incomplete involvement with normal 
amplitude, and the rest of patients incomplete involvement 
with low amplitude(11). NCV and EMG disturbances in both 
the upper and lower extremities are frequently treated as 
symmetric(25). In fact, the available documents posed long 
term axonal neuropathy in these patients(63). 
The symptoms and complications of sulfur mustard 
poisoning and cardiovascular system were chest pain and 
palpitation which were the most frequent symptoms and 
hypertension was the most common complication (49). In 
electrocardiography (ECG) findings, there are no heart 
abnormalities among the sulfur mustard exposed victims in 
the acute phase in hospitals, but Karbasi- Afshar et al. (2017) 
reported some disturbances in  the exercise test and 
echocardiography (65). Moreover, the incidence of coronary 
atherosclerotic lesions among these patients was 
significantly higher than the control group; although, the 
type of lesions was not different (66). Shabestari et al (2011) 
suggested coronary artery ectasia (CAE), a late toxic effect 
of sulfur mustard in veterans. The prevalence of coronary 
artery ectasia in these veterans was 7.5 times more than non-
exposed individuals. Besides the most generally involved 
artery in these victims was the left anterior descending 
(LAD) artery (67). Cardiac dysrhythmias occur in the 
indication exposure to high doses of sulfur mustard (68). In 
these victims, it seem that coronary artery diseases, 
especially coronary ectasia, and ventricular dysfunction can 
cause noticeable cardiovascular abnormalities(65). 
■Laboratory Diagnostic Tests 
Sulfur mustard urinary metabolites are appropriate for 
detecting its contamination, but the most difficult diagnosis 
is the rapid elimination of sulfur mustard. Protein 
macromolecular adults could play an important role as long- 
term biologic markers of sulfur mustard exposure (22, 69). 
There are four main metabolic pathways and four types of 
sulfur mustard biomarkers in urine, blood and blister 
exudates, as well. The first pathway involves the direct 
oxidation product of sulfur mustard, bis-ß- chloroethyl 
sulfoxide (SMO), the directly hydrolyzed metabolite 
thiodiglycol (TDG), and its oxidation product thiodiglycol 
sulfoxide (TDGO).  
The second pathway involves a reaction with numerous 
glutathione, then can undergo oxidation change to the 
sulfone by ß-lyase cleavage. It can lead to formation of 1, 1’- 
sulfonylbis [2-S-(N-acetylcysteinyl) ethanol] ((SBSNAE), 1, 
1’- sulfonylbis [2- (methylthio) ethane] (SBMTE), 1-
methylsulfinyl-2- [2-(methylthio) ethylsulfonyl] ethane 
(MSMTESE) and 1, 1
’
- sulfonylbis [2-(methylsulfinyl) 
ethane] (SBMSE).  
The third pathway is the reaction on the certain 
nucleophilic sites in DNA to produce SM-DNA adducts. The 
main sites of DNA alkylation by sulfur mustard include N
7
, 
O
6
 positions of guanine, N
3
 position of adenine, and 
interstrand or intrastrand crosslinks at the N
7
 position of 
guanine, and adducts of N
7
-[2-[(2-hydroxyethyl) thio] ethyl]-
guanine (N
7
-HETEG), O
6
 -[2-[2-hydroxyethyl) thio] ethyl]- 
guanine (O
6
-HETEG), N
3
- [2-[(2-hydroxyethyl) thio] ethyl]- 
adenine (N
3
-HETEA), and bis [2-(guanine-7-yl) ethyl] 
sulfide (Bis-G). The fourth pathway involves the reaction 
with different amino acid residues present in proteins, among 
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which are the HETE-valine (HETE-Val) adduct of 
hemoglobin and HETE-cysteine adduct of albumin (69, 70).  
● Diagnosis of urinary metabolites of sulfur mustard 
The urine samples are collected to determine free and 
conjugated forms of the simple hydrolysis product 
thiodiglycol (TDG) and TDG sulfoxide (TDGO) [its 
oxidized form]. Free TDG, free plus conjugated TDG (total 
TDG), free TDG+ TDGO, and free plus conjugated TDG + 
TDGO (total TDG + TDGO) could be evaluated. Liquid 
chromatography- mass spectrometry (LC-MS) and gas 
chromatography- mass spectrometry (GC-MS) methods are 
carried out to analyze the samples(69, 71). TDG and TDGO 
have low concentrations in human urine. The measurable 
amount of total TDG + TDGO excreted in urine during the 
first five days accounted for 0.5-1 % of the practical dose of 
sulfur mustard. Therefore, this diagnostic method will be 
useful for a short term (11, 71). 
GC-MS and GC-MS-MS (detection limits lower than 0.1 
ng/ml), were developed for the analysis of the ß- lyase 
metabolites in urine of the victims (72). Nowadays, rapid 
method is introduced to analyze the ß- lyase metabolitis in 
urine using LC-MS-MS with electrospray ionization (ESI) 
detector. LC-MS-MS provides an alternative to GC-MS-MS, 
to avoid the conversion of the metabolites to a less polar and 
more volatile analyte (73). 
● Diagnosis of sulfur mustard adducts with DNA 
DNA and protein adducts have partly longer times from 
week(s) to months and can be used as good biomarkers for 
analysis. DNA has large affinity towards alkylating agents, 
which is the exact reason for the cytotoxicity of sulfur 
mustard. The main site of actions is the N
7
, O
6
 position of 
guanine and N
3
 position of adenine about DNAs to be 
alkylated by sulfur mustard. As explained, there are four 
kinds of sulfur mustard-DNA adducts, for recognizing and 
using biomarkers, i.e., N
7
-HETEG, Bis-G, N
3
-HETEA, O
6
-
HETEA.Based on an in vitro study, in calf thymus DNA or 
human blood, N
7
-HETEG has the most quantity (61%), Bis-
G (16%), N
3
-HETEA (11%), O
6
- HETEG has the minimum 
amount (0.1%) of the total sulfur mustard-DNA. However, 
O
6
- HETEG has the minimum percentage, but it is the main 
responsibility of DNA damaged by sulfur mustard (70). The 
enzyme - linked immunosorbent assay (ELISA) is applied 
for detecting DNA-sulfur mustard adducts (74). 
● Diagnosis of Sulfur Mustard adducts with proteins 
Because the metabolites cannot be detected in urine for a 
long time, therefore protein adducts to blood are a potential 
tool to assess exposure. Hemoglobin and albumin are two 
numerous proteins in blood that can be simply separated to 
determine sulfur mustard adducts(11). A number of adducts 
(histidine residues, glutamic acid residues, and both of the 
N-terminal values) N1 and N3 histidine adducts were found 
to be most abundant, and it was the alkylated N- terminal 
valine adducts that were most useful for next measurement 
(75). Sulfur mustard forms adducts to hemoglobin at valine, 
glutamic, and histidine residues can be available around 120 
days. Furthermore, sulfur mustard can form stable adducts to 
human serum albumin (HAS) at its reactive cystein-34 
residue. Its half-life is shorter than hemoglobin, and is 20 to 
25 days. Sulfur mustard binds to the single reaction cystein 
residue of human serum albumin, which contains a stable-
hydroxyethylthioethyl [S-HETE] adduct. S-HETE adduct 
can be used as a long-term biomarkers of sulfur mustard 
exposure in humans. It can be measured using LC-MS-MS 
(76).  
■ Treatment 
● First aid measures and triage 
Victims should be transferred to a safe area as soon as 
possible. All victims’ clothes should be taken off and 
discarded. The skin should be rinsed with tap water and 
neutral soap (pH near 7). Rubbing and dry cleaning the skin 
may increase penetration of sulfur mustard into bloodstream. 
Whenever contamination occurs in the area affected with 
liquid mustard, eyes should be washed with large volumes of 
water, normal saline or ringer solution. Then the victims 
should be transferred to a medical center or hospital (77, 78). 
After chemical warfare agents (CWAs) release, a triage 
program should be performed in the clean area (warm zone) 
to determine the priorities for resuscitation, decontamination, 
pharmacological therapy, and transport to hospital. Triage is 
a dynamic process and should be carried out continuously in 
both contaminated (hot zone) and clean zones. The triage 
programs include; T1 (immediate or urgent): victims who 
need medical care and advanced life support within a short 
time on the event location and in the hospital. T2 (delayed) 
victims with injuries who are in need of prolonged care and 
require hospitalization, but delay of this care does not affect 
the prognosis of the event. T3 (minimal): victims who have 
minor injuries who will not be evacuated and will be able to 
return to duty in a short time. T4 (expectant): victims with 
fatal injuries who will probably not survive in the medical 
care available before reaching terminal care (78). According 
to the colors and seriousness of exposure at the battlefield, 
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red, yellow, green, and black colors were set for immediate 
or urgent, delayed, minimal, and expectant classes (79). 
● Medical treatment  
■ 1) General treatment and suggested antidotal 
treatment 
In clinical conditions, it is possible to use sedative to 
control the patient’s pain and induce relaxation (22). At 
present, there is no proven evidence of clinical and 
therapeutic effects on the use of extracorporal detoxification 
procedures, such as hemoperfusion and hemodialysis (22). 
There are no recognized antidotes by official sources for 
sulfur mustard. Although based on studies on laboratory 
animals to protect the toxic side effects of alkylating agents, 
sodium thiosulfate has been introduced as its antidote. But 
there are no supplementary clinical reports to confirm it and 
it is not recommended to use in intoxicated persons (5). 
■ 2) Special systems’ care 
◘ 2-1) Skin lesions management 
The treatment plans are based on reducing the risk of 
acute and chronic sequelaes (5). After the victims 
contaminated clothes being gently removed, the historical 
advice is to rinse exposed skin with tap water and neutral 
(pH of near 7.0) soap. Some experts believe that the skin 
could be washed with home bleach solution or hypochloride 
0.5% solution. Other researchers considered that the skin 
was washed with chloramines -T 0.2%- 0.3% solution at 
least six times a day (13, 77). A wide variety of solutions is 
presented in the theoretical discussion of this problem, 
including water, normal saline, sodium bicarbonate 1.5% 
solution, saturated sodium sulfate or magnesium sulfate 
solutions (hypertonic solutions), boric acid solution, 
dichloramine -T 0.5% solution in a solvent, and dilute 
solutions of sodium hypochlorite or potassium permanganate 
solution 1/10000 and warm water. The important point is 
that there are no studies in either laboratory animals or 
humans systematically, which put forward the benefits of 
any therapeutic approach, compare them, and prioritize each 
of them (5).  
At first, the skin is pale and then it becomes 
erythematous after several hours. Blisters do not usually 
appear until the second day, and develop for a few days. 
Therefore, for areas of erythema and small blisters (≤ 2 cm) 
there is the use of soft lotions such as calamine and local 
steroid solutions. This action reduces itching and irritation 
(22, 80). Besides, the use of topical bacteriostatic agents, 
such as silver sulphadiazine 1% (Flamazine) could prevent 
secondary infections. One of the common problems is the 
moderate pain and itching, and it is possible to use mild 
analgesics, antihistamines and low doses of diazepam. In 
severe pain there is a need to use narcotics such as morphine 
sulfate (80). According to a study, Panahi et al. compared the 
combination of phenol1% and menthol 1% to relieve itching 
and other skin lesions with the placebo group. They found 
significant differences before and after treatment with the 
mentioned drugs. As a result, they recommended the 
combination of phenol1% and menthol1% in the treatment of 
chronic skin lesions due to sulfur mustard exposure (81). 
Panahi et al. compared the effect of pimecrolimus cream 1% 
(an immunosuppressant which inhibits calcineurin in skin) 
and betamethasone cream 0.1%.in chronic skin lesions after 
sulfur mustard exposure. This study showed that the effect of 
pimecrolimus cream 1% is better than betamethasone cream 
0.1% in the control of pruritus, burning sensation and dry 
skin, specialty in the thorax, back and upper extremities (82). 
To eradicate chronic skin lesions, another study has been 
performed by Panahi et al. They used doxepin cream 5% or 
betamethasone cream 0.1% twice daily for 6 weeks. Both 
groups showed significant progress regarding pruritus, 
burning sensation, skin dryness, and skin scaling. The 
lesions of all areas significantly reduced after treatments, 
except on the head, face, and genitalia. This study posed the 
same efficacy between doxepin cream 5% and 
betamethasone cream 0.1% .Therefore, doxepin 5% is a 
potential alternative to control pruritus and other skin lesions 
(83). At last, in a study by Shohrati et al, they used oral 
drugs such as cetirizine 10 mg, doxepine 10 mg, 
hydroxyzine 25mg daily for 4 weeks. Hydroxyzine 25 mg 
once daily has equal result in comparison to doxepine 10 mg 
once daily, but more than cetirizine 10 mg once daily in the 
control of chronic pruritus in these patients (84). 
In patients with delayed cutaneous complications of 
sulfur mustard exposure (DCCS), has shown that capsaicin 
(0.025% as cream) decreased the scaling of pruritus and skin 
dryness less than betamethasone (0.1% cream), but the 
burning sensation in capsaicin-treated group was higher than 
the control (85). 
After these measures, the therapeutic approach with 
blisters is as follows; the small blister (≤ 2 cm) will remain 
intact and does not get debridement. However, they have 
ruptured spontaneously. Debrideinent may help to increase 
healing process. In the blister (> 2cm), the liquid is 
evacuated by syringe or incision, then the debridement is 
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done, washed with normal saline and dressed with silver 
sulfadiazine (11, 13, 77). Sulfur mustard causes large scale 
damage to the skin from superficial to deep dermal, as well 
as full thickness burn in humans. This injury depends on 
damage to the DNA. This point may delay or prevent the 
effective replication of the keratinocytes. Failure to 
replication causes long healing process, it means, confronted 
with damage dermal , also a lack of a favorable matrix on the 
new epidermal (86, 87). A term called “dermabrasion” 
means to remove the necrotic surface from the burn area, 
active regeneration of new epidermis from viable epithelium 
at the edge of the wound. In addition, debridement with laser 
(lasablation) facilitates wound healing at the cellular level, 
and is done in different ways; Powered dermabrasion, pulsed 
CO2 laser ablation, and Erbium: yttrium-aluminum-grant 
(Erb: YAG) laser ablation could accelerate the rate of 
healing of full thickness skin. In severe and extensive burn, 
skin graft may be required (48, 86, 87). 
◘ 2-2) Management of the respiratory toxic effects 
Nature of sulfur mustard induces lung damage and the 
word “mustard lung” is used to support specific entity. The 
best time to start treatment interventions in acute phase is 
when the clinical signs have been seen. After the acute 
phase, long term disability is the greatest problem in this 
system for people exposed to sulfur mustard (88). 
● Physiotherapy & Oxygen therapy 
The foundations of the treatment in these patients are 
respiratory physiotherapy, oxygen therapy, antibiotics, and 
mechanical ventilation (89). Respiratory rehabilitation plays 
an important role in the medical treatment of patient with 
sulfur mustard. Respiratory physiotherapy included postural 
drainage and chest percussion and vibration (90). Long term 
supplemental oxygen therapy and nasal intermittent positive 
pressure ventilation has been ordered (88).  
Heliox, a mixture of helium: oxygen (79:21) instead of 
air: oxygen (79:21) with non-invasive positive pressure 
ventilation (NIPPV) can be used in constricted airways with 
less turbulence. This method decreases dyspnea and work of 
breathing, reduces intrinsic positive end expiratory pressure 
and dynamic hyperinflation. Moreover, it had beneficial 
effects on systolic, diastolic and mean arterial pressure, pulse 
rate, respiratory rate and dyspnea, also higher arterial oxygen 
saturation (85, 91).  
●Antibiotics (Macrolide Antibiotics) 
Sulfur mustard inhalation causes inflammatory 
responses, followed by respiratory dysfunction. One of these 
disorders is secondary infections. Antibiotics are 
recommended to decrease or eradicate secondary infections. 
In patients with bronchiolitis, because of no response to full 
dose corticosteroids, prednisone and azithromycin may be 
helpful. Moreover, a combination of clarithromycin and 
actylcysteine for 6 months was effective in chronic 
bronchitis and bronchiolitis (90, 92). 
Macrolide antibiotics have shown effectiveness in 
different chronic respiratory diseases such as diffuse 
panbronchiolitis (DPB), asthma, cystic fibrosis, chronic 
bronchitis, and chronic sinusitis (92). Macrolides have anti-
inflammatory and immunomodulatory effects and the 
famous macrolides are; erythromycin, clarithromycin, 
roxithromycin, azithromycin, and josamycin. Macrolides can 
have reduced airway inflammation with various 
mechanisms. The important point is the lack of eosinophilic 
inflammation (neutrophil mediated inflammation). In non-
eosinophilic inflammation, macrolides are the best choice 
among antibiotics to play anti-inflammatory role. These 
mechanisms include reduced airway mucus secretion, and 
anti- inflammatory properties including decreased airway 
neutrophil collection in the expression of pro-inflammatory 
cytokines, e.g., interleukin (IL-6,IL-8), also CRP, RF and the 
increase expression of markers of inflammation which 
include cyclooxygenase-2 (COX-2), tumor necrosis factor 
alpha (TNF α), inducible nitric oxide synthase (iNOS), 
matrix metalloproteinase-9 (MMP-9) and a notable increase 
in total protein, IL-1α and IL-13 (88, 93). 
●Bronchodilators 
Bronchodilators can be used in patients with enhanced 
airway hypersensitivity, plus people with moderate to severe 
lung injury due to sulfur mustard exposure. The combination 
of ß- agonist (e.g., salbutamol, trade name; albuterol, 
ventolin) and an anticholinergic (e.g., iprotropium bromide, 
trade name; atrovent) is more effective than any other 
bronchodilators if used alone(94).Bronchodilators can 
reverse signs and symptoms in asthma and airway 
obstruction. They cause to improve characteristics of 
pulmonary function tests (PFTs). Prescribing 200 µg of 
salbutamol is remarkably inhalable to improve PFT in these 
patients.‏Furthermore, they undertake to decrease pulmonary 
complications such as severe bronchial stenosis and loss of 
ciliary movement that is directly related to chronic infections 
and bronchiectasis. In addition, some victims suffered 
obstructive airway disease after long- term exposure, 
bronchodilators could decrease or resolve it (95). 
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●Corticosteriods 
Corticosteriods are extensively used to resolve 
respiratory signs and symptoms of mustard lung. Of course, 
the use or non-use corticosteroids in these patients is 
discussed and being controversial. However, some studies 
have shown that they are used to manage severe chronic 
bronchitis like most asthmatic patients. It is noteworthy that 
inhaled corticosteroids can progress pulmonary function in 
these patients, and this has a synergistic effects with inhaled 
ß-2 agonist bronchodilators (96, 97). In patients exposed to 
sulfur mustard suffering from chronic bronchiolitis, a 
combination of inhaled corticosteroids, long- acting ß-2 
agonists is recommended. Moreover, the medium dose of 
fluticasone/ salmeterol would have a similar effect as taking 
high doses of beclomethasone with short-term beta-agonist 
for airway reversibility (96, 98). 
●N-acetylcysteine (NAC) 
Long term use of corticosteroids causes adrenal 
suppression, osteoporosis, and sodium retention. In parallel 
with this point, patients who do not respond well to 
bronchodilators, based on a series of researches N-
acetylcysteine (NAC) can be helpful. NAC that is a thiol 
compound, and chemical formula C5H9NO3S can be an 
appropriate substitute instead of old and traditional 
treatments (99, 100). 
People exposed to sulfur mustard have structural changes 
in their lungs. These changes cause irreversible injury of 
parenchyma and airway walls. In these patients, 
inflammation and oxidative stress play a main role in the 
phathogenesis of many disorders in respiratory systems 
(101). Glutathione (GSH) is the principle thiol contribute in 
cellular redox reactions. It is involved in the detoxification of 
most endogenous and exogenous toxic substances. GSH is 
released in cellular response to xenobiotics, free radicals, 
reaction oxygen species (ROS), and other origins of cellular 
damage (102). In fact, available data in vitro and in vivo 
showed that NAC protects the lungs against toxic agents, in 
two ways; first, the increase of pulmonary defense 
mechanism with direct antioxidant properties, second, is the 
indirect role as a precursor of GSH synthesis (101). Bobb et 
al. (2005) and also many other researchers claimed; N-
acetyl-L-cysteine (NAC) is a candidate chemoprophylaxis 
substance for sulfur mustard exposure in humans, in general, 
it is has a clinical application (102).There are many studies 
that confirmed the helpful effects of NAC in humans such 
as; preserve oxidant- antioxidant homeostasis due to 
increasing GSH, decrease in the amount and the activity of 
inflammatory cells and ROS production, prevent the release 
of several inflammatory mediators in various pathological 
situations, decrease the secretion of several inflammatory 
modulators, and reduces product ROS (99, 103). 
NAC administered orally a maximum dose of 600 
mg/daily, or 1200 mg/daily, 1800 mg/daily, confirmed the 
useful effect of N-acetylcysteine on intensity scale. High 
dose NAC for high risk patients with severe conditions and 
or those patients who are still in a moderate phase of the 
disease (103). The authors of this article believe that many 
studies require high dose (1200 mg/ daily and 1800 mg/ 
daily) of NAC that is more effective than 600 mg or not. 
Now, some researchers and experts accept this subject and 
others reject it. Based on approved studies, therapy of NAC 
may improve the lung function. 
● Recombinant tissue plasminogen activator (rt-PA) 
The FDA has approved recombinant tissue plasminogen 
activator (rt-PA) in long-term chronic sequelae of sulfur 
mustard inhalation exposure, such as bronchiolitis obliterans 
(BO) and pulmonary fibrosis. It is directly delivered to the 
airway using bronchoscopy(104). 
●Interferon gamma-1b (INFγ- 1b) 
Exposure to sulfur mustard or mustard gas causes 
disorders such as inflammation respiratory system. 
Transforming growth factor ß1 (TGF- ß1), an isoform TGF-
ß, plays an essential role in some of the pathogenesis of 
respiratory system. TGF-ß, specially TGF- ß1 is enhanced in 
patients exposed to sulfur mustard. Also, IFN-γ 1b is a 
bioengineered form of interferon gamma. IFN-γ had anti-
inflammatory effect via downregulation of TGF- ß and type 
land III procollagen gene expressions. As level of TGF- ß 
increased, IFN-γ may be effective in pathologic situation. 
Interferon gamma-1b (200 µg) three times per week 
subcutaneously and low dose prednisolone (7.5 mg) once a 
day orally for six months could improve dyspnea indices and 
pulmonary function tests, a decrease in hospitalization time, 
an increase in arterial oxygenation of sulfur mustard exposed 
with severe delayed lung complications(88, 90, 105, 106). 
●Sildenafil and Tadalafil 
Sulfur mustard poisoning can lead to pulmonary arterial 
hypertension (PAH) (107). This disease is determined by 
proliferation and regeneration in these vessels. PAH 
increases in pulmonary vascular resistance (PVR) and finally 
induces right ventricular failure and death(108). Recently, 
several new drugs in phosphodiesterase -5 (PDE5) inhibitors 
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have been approved by Food and Drug Administration 
(FDA) for the treatment of pulmonary arterial hypertension. 
PDE5 inhibitors increase cellular cGMP in vascular smooth 
muscles. This action will cause vasodilation [e.g., pulmonary 
artery smooth muscle cells (PASMCs] and decreases 
pulmonary vascular resistance (PVR), pulmonary vascular 
resistance index (PVRI), PVR/SVR ratio and pulmonary 
arterial pressure (PAP), also cardiac output (CO) increase. 
One of these drugs introduced in 2005 is the sildenafil (107, 
109, 110). 
Sildenafil would be in a starting dose of 12.5 mg three 
times daily. Then the dose is gently increased to 150 mg/day 
every 12 weeks. The optimal dose of sildenafil for PAH is 
not certain. Although this dose may be various in clinical 
managements, satisfactory effects have been reported over to 
500 mg/day (110). On the basis of studies, sildenafil is a 
better selection, because it is effective, simply accessible, 
relatively cheap, simple to use, and very well-tolerated 
without any main side effect. It may be the first choice drug 
for PAH patients (110, 111).  
Tadalafil 
According to tadalafil’s structure, it has different 
pharmacokinetic properties and longer half-life compared to 
sildenafil (the terminal half-life of sildenafil is 3-5 h). It is 
assigned in the treatment of pulmonary arterial hypertension. 
Tadalafil is prescribed 2.5 mg, 10 mg, 20 mg, or 40 mg daily 
for 16 weeks (108). 
●New Therapeutic approach & Herbal therapy 
Using hypertonic solutions, such as mannitol and 
hypertonic saline have several effects on the respiratory 
system. There are numerous studies that mentioned the 
significant effects of these agents on this system, including 
the most important; developing an osmotic gradient as the 
flow of water is pushed towards the airway lumen, which 
caused reduced viscoelasticity, surface tension, contact angle 
and sputum content. Therefore, inhaled mannitol is a suitable 
alternative as anti- inflammatory therapy in COPD, avoid 
using inhaled steroid treatment, and prevent overtreatment of 
COPD. Besides other effects are the increased mucus 
hydration and mucociliary clearance is reduced. also reduced 
airway wall edema. Nebulization with 5% hypertonic saline 
proved which one performs that is simple, cheap, easily 
applied, safe, and seemingly an effective treatment could be 
generalized for use in clinics, infirmaries, army and general 
hospitals. It may be remarkable to current treatment 
[bronchodilator therapy (albuterol/ salbutamol or 
epinephrine), corticosteroids and nebulized normal saline]. 
This method has been able to improve the severity of 
bronchiolitis, cystic fibrosis and reduces the length of stay in 
the hospital (112-115).Usually herbal and non-chemical 
agents (phytomedicine) are used in patients who have poor 
response to common and conventional chemical drugs as an 
alternative choice for relieving, obliterating or eradicating 
(116). 
Thyme with scientific name “Thymus Vulgaris”, is a plant 
from Labiatae. With strong expectorant, reduces 
bronchospasm, relieves inflammation and coughing 
properties. Other effects include increased ciliary clearance, 
pause in cholinergic tone, increased vascular continuity, and 
cease of the release of chemical intermediates from mast 
cells and basophils. Dosage of thyme to 15 drops of 2% in 
glass water after each meal (117).Zataria multiflora (ZM) 
[Shirazi Avishan] is from the Labiatae family, a flowering 
plant similar to thyme (Thymus vulgaris). Its leaves are used 
in herbal medicine. Its extract has antibacterial and anti-
inflammatory effects. It is generally used as an antiseptic and 
antitussive for the treatment of respiratory system disorders. 
This point is confirmed and recommended in many studies 
(116, 118). In general, Thyme extract is useful in upper 
respiratory infections. In addition, Zataria multiflora (ZM) is 
used to treat common cold. It has been approved for its 
efficacy and safety (116).  
Another herbal medicine is the combination of 
Thymefluid extract and Primrose root tincture at a dosage of 
30 drops (1 ml), receive orally five times a day, which is a 
safe and well tolerated treatment for patients. It reduces the 
symptoms of bronchitis and the duration of acute bronchitis 
is shortened (119, 120). The other combination contains Ivy 
leaves, Thyme herb, Aniseed and Marshmallow root. This 
herbal syrup seems to reduce the cough from common cold, 
bronchitis and mucus formation in the respiratory system 
diseases (121). Combination of two types of herbals, such as, 
Thyme herb (thyme herba) with secretolytic, expectorant, 
bronchospasmolytic, antibacterial and antiphlogistic 
properties and Ivy leaves (5.4 ml three times daily for 11 
days) are used. The combination is well-tolerated and seems 
to be a favorable altenative therapy. There is no risk for the 
progress of resistant pathogens, when repeatedly used in 
mild respiratory system infections (122). 
Nigella sativa has a histamine antagonist and inhibitor of 
the histamine receptor. Also, it is affirmed as anti- 
inflammatory, antitussive and anticholinergic (123). Boiled 
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aqueous extract of Nigella seed was used on chemical war 
victims. Extract of Nigella sativa improved symptoms and 
PFT values in these victims(90). Pelargonium sidoides 
extracts are spaciously used in the treatment of respiratory 
system infections. They have antimicrobial and anti-
inflammatory properties. They release tumor necrosis factor 
α (TNFα), nitric oxide, and increased natural killer (NK) 
cells activity. Therapeutic dosage is 30 drops three times per 
day for at least seven days. Moreover, extract Pelargonium 
sidoides is available on the market in the form of 10, 20, 30 
mg tablets, which can be used three times a day (123). 
One of the herbal drug is curcumin. There are so many 
documents of which prove that curcumin has an anti-
inflammatory propetions. Generally, it can be a regulated 
different pro-inflammatory gene in various cells (124). In 
addition, it has antioxidant and free radical scavenging 
activity properties because it can prevent membrane lipid 
peroxidation as well as oxidative DNA damage(124). 
Therefore, it seems that it can affect on the control of 
severity of sulfur mustard damage disorder(88). 
Curcuminoids are phytochemicals with significant anti-
inflammatory properties used in patients who were suffering 
from chronic sulfur mustard- induced pulmonary 
complications. They are orally adminisered at 500 mg T.I.D 
for 4 weeks(125). In patients with delayed respiratory 
complications of sulfur mustard (DRCS), some 
pulmonologists offer the combination of curcuminoids (1500 
mg/day) and piperine (15 mg/day) for 4 weeks. This 
combination improves FEV1/FVC and may decrease 
inflammatory mediators, including interleukins 6 and 8, 
tumor necrosis factor-alpha (TNF-α), transforming growth 
factor- beta (TGF-β), high-sensitivity C-reactive protein (hs-
CRP), calcitonin gene-related peptide (CGRP), substance P 
and monocyte chemotactic protein-1(MCP-1) (85, 126). 
Today, phytomedicine has become a part of pharmaceutical 
market and treatment in Asia and Europe. Herbal medicines 
have safetiness, efficacy and quality. It is then used alone or 
with conventional medicines (123). Finally, there is a strong 
evidence of the use of herbal medicines to control the 
severity of the disease in patients exposed to sulfur mustard. 
Of course, all these cases will require more researches with 
more samples. 
● Admitted to ICU 
In victims with severe injuries of the respiratory system, 
due to damages occurring in the process of injury, the need 
for hospitalization in the ICU departments will be more 
special to monitor the patients and treatments more precisely 
(22). 
◘2-3) Eye lesions management 
2-3-1) General measures and medical treatment 
Eye damage is the most incapacitating effect of military 
force and civilian people. It has been pointed to cause many 
term eye problems (5).The eyes of victims must be washed 
as early as possible at the first 10-15 minutes after exposure 
even if these victims did not have any symptoms in their 
eyes. Since sulfur mustard induces rapid and irreversible 
reactions with eye tissues, irrigation technique of eyes is not 
effective after this time (11). 
Too much irrigation with water, normal saline, sodium 
bicarbonate 1% or 1.5%, dichloramine –T 0.5%, saturated 
solution of boric acid, liquid albolene, dilute solution of 
sodium hypochlorite or potassium permanganate and olive 
oil. There are no proven studies in animals or humans among 
all these solutions that are more effective than tap water (5, 
11, 89). Meanwhile, pads, gauzes and bandages must not be 
used for the eyes, because they cause worse effects to eyes. 
This action can lead to raise temperature in the damaged 
eyes and create lesions (13). In addition, local anesthetic 
drops should be avoided in both the healthy and injured 
corneas for ophthalmologic examination (11, 13). 
The use of dark sunglasses was offered to victims with 
photophobia. (13). In general, local steroids must be 
prevented if there is an evidence of corneal epithelial defects. 
Although these agents can reduce chemosis and corneal 
epithelial edema (22). 
Mydriatic drops e.g., cyclopentolate and atropine can 
reduce ocular pain because of spasm of the ciliary muscle 
and prevent posterior synechiae. Antibiotic drops e.g., 
sulfacetamide, neomycin, gentamicin, and acidamphenicol, 
polymyxin-B- sulfate are used to prevent secondary bacterial 
infections and topical antiglucoma medications to control 
intraocular pressure (IOP) (31, 35). An anti-inflammatory 
treatment will be useful for a short period of time after 
exposure to sulfur mustard (specially at the start of the first 
hour) for a week or for symptomatic treatment in the 
formation of corneal neovascularization (NV). Using 
dexamycin (dexamethasone+neomycin) as an anti-
inflammatory agent reduces the symptoms of the eyelid, 
conjunctiva, and cornea. Clinical observations and specific 
detection reduce about 50% in severity of corneal injuries 
following treatment, but dexamycin will have no effect on 
cornea erosion. By measuring the thickness of the cornea, 
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reducing the thickness and edema, and these agents will also 
reduce neovascularization. Given these points, the use of 
dexamycin and other anti-inflammatory drugs is confirmed 
(24). Matrix Metalloproteinase (MMP) inhibitors, like 
tetracycline and doxycycline inhibit the activity of MMP 
with independent mechanisms, in addition to having 
antimicrobial character. They have anti-inflammatory 
properties to reduce acute and delayed injuries and reduce 
the formation of neovascularization in the cornea. The 
potential value of tetracycline in the treatment of moderate to 
severe eye injury in the past has been shown. The 
mechanisms include, limited gene expression of neutrophil 
collagenase and epithelial gelatinase, prevention of alpha1- 
antitrypsin degradation, and removal of reactive oxygen 
species (ROS) (24, 127). 
2-3-2) Surgical Interventions 
Eye injuries because of contact with sulfur mustard are 
divided in two categories; acute, chronic and delayed. Most 
victims with acute clinical manifestation recover to a 
completely normal state after a few weeks, but chronic and 
delayed mustard gas lesions usually cause developed and 
permanent decrease in visual acuity and even blindness. One 
of the chronic and delayed complications is mustard gas 
keratopathy (MGK) that includes about 0.5% to 1% in cases 
with severe exposure. It usually happens and is hard to treat 
this condition (28, 128). Other findings include: disabled 
corneal sensation, recurrent/resistant epithelial erosion, 
damaged limbal vasculature, neovascularization, corneal 
irregularity and thinning, descemetocele and sometimes 
perforation (28, 31, 128). 
●Tarsorrhaphy 
If thinning of the cornea is advanced in nasal or temporal 
zone with or without persistent epithelial defects (PEDs), 
medial or lateral tarsorrhaphy can be used to prevent the 
progress of corneal thinning (28, 31, 129). This procedure 
greatly reduces the symptoms of chronic irritation of the eye 
surface and the dry eye, and results in healing (31). This 
method is increasingly applied after stem cell or corneal 
transplantation(30, 129).  
● Human Amniotic Membrane Transplantation 
Using amniotic membrane in conjunctival plastic surgery 
had previously been introduced(130). It is thinner and more 
tolerable to the patients. It is avascular, multilayered tissue 
with antiangiogenic, antiscarring and anti-inflammatory 
properties. Because it does not express antigens of 
histocompatibility, the membrane will never be rejected after 
transplantation. Using cryopreserved methods the useful 
effects of decreasing inflammation and neovascularization 
persist for a long time (131). 
Amniotic membrane (AM) has many uses, which are 
either graft as an alternative in damaging ocular surface 
stromal matrix or as a patch (dressing) in preventing 
unwanted inflammation the result ocular surface damage. Of 
course, it can also be used in combination (131). Limbal 
stem cell deficiency can occur due to the degradation of 
limbal epithelial stem cells and/or limbal stroma (niche) 
inefficient (129). While a persistent epithelial defect (PEDs) 
is associated with partial limbal stem cell deficiency 
(LSCD), an amniotic membrane transplantation can be used. 
Even if it involves as large as 120° to approximately 360° in 
the limbus. The result in the eyes was a smooth and stable 
corneal epithelial surface without erosion or persistent 
epithelial defect, less stromal cloudiness and vascularization 
eventually. If LSCD is severe, the amniotic membrane 
transplantation is not helpful (23, 132). An important point is 
the use of suture in the corneal epithelial defect, which 
epithelium may grow under amniotic membrane. Therefore, 
instead of suturing using fibrin glue, this will prevent the 
formation of epithelium under amniotic membrane(133). 
Whenever severe eye irritation occurs with disturbing 
photophobia, which is followed by lipoid deposition in the 
cornea, superficial keratectomy associated with amniotic 
membrane transplantation becomes very useful (23).It 
should be noted that multiple amniotic membrane 
transplantation may be effective in the treatment of deep 
ulceration of the cornea and sclera (130). 
●Stem Cell Transplantation 
The patients with mustard gas keratitis (MGK) have 
problems such as irritation, redness, and tearing of the eyes 
with persistent epithelial defects (PEDs), dry eyes, stromal 
neovascularization, focal corneal thinning and ulceration, 
also loss of keratocytes and endothelial cells, and lipid and 
amyloid depositions. In this situation, they do not respond to 
conservative and regular treatments and may require stem 
cell transplantation (23, 30, 128, 129). 
If total limbal stem cell deficiency (LSCD) involves only 
one eye, limbal conjunctival autograft transplantation can be 
achieved, but total LSCD may complicate both eyes, and 
limbal epithelial stem cells for allogeneic source can be used 
(134). Limbal stem cells are harvested from carriers, 
including parents, siblings, or children, known as living-
related conjunctival-limbal allograft (lr-CLAL) or the 
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cadaveric eyes known as keratolimbal allograft (KLAL) 
(135). Tissue harvested from one eye or two eyes from 
family members by lr-CLAL method is newer and 
genetically closer to cadaver by KLAL methods. But a 
KLAL graft is more available and it has more stem cells. In 
addition, it is weak stem cells and reject chronically (23). It 
is noteworthy that adjacent to the limbal areas are the 
thinnest parts of the peripheral cornea with epithelial defects. 
These areas can be selected as surgical sites (23, 129). Due 
to its partial, bilateral and non-symmetrical LSCD, and the 
difference in severity of the involved quadrants, 360- degree 
coverage of the limbal region with a graft that is inessential 
(129). To prevent rejection of corneal grafts, 
immunosuppressant drugs are used. For prophylaxis and 
treatment, these drugs including topical and systemic 
steroids (prednisone; 0.5 mg/kg/day P.O), cyclosporine A; 
2.5 mg/kg/day P.O, tacrolimus (FK506); 0.2 mg/kg/day P.O, 
mycophenolate mofetil; 2gr/day P.O are used (136). 
●Corneal Transplantation 
If LSCD is not severe and central corneal opacification 
caused a decreased visual acuity, penetrating keratoplasty 
(PKP) or lamellar keratoplasty (LKP) has been used (28, 30). 
Many studies pointed to corneal layer damage in chronic and 
delayed mustard gas keratitis. These abnormalities were 
observed in all corneal layers, but severity of anterior to 
middle parts is more than the posterior parts(128). Deep 
lesions need a full-thickness graft (23). In the eyes with 
severe corneal thinning, large descemetoceles, and the 
possibility of corneal perforation is high, may require 
tectonic PKP, and in patients with small descemetoceles may 
carry out tectonic LKP (23, 30). 
One of new procedures is called deep anterior lamellar 
keratoplasty (DALK) or deep lamellar keratoplasty (DLK). 
DALK can be presented to patients with normal endothelium 
without deep posterior stromal scars to descement 
membrane. It performs the deepest level to decrease scarring, 
also has same thickness of the posterior layer, a donor tissue 
of suitable thickness, good arrangement of the edges of the 
graft, and identical traction of the sutures (137). 
The benefits of the DALK include: decreased endothelium 
graft rejection (138), maintaining of host endothelium with 
minimal surgical trauma and cell count (139, 140), effective 
visual rehabilitation to PKP (141), as well as less 
intraoperative and postoperative complications (139). DALK 
is better to PKP for protection of endothelial cell density. It 
is a long-term graft survival time, also it is safer than PKP 
because is an extraocular method (137). Corneal 
transplantation can be performed with limbal stem cell 
transplantation at the same time, but experts are 
recommended to perform that for at least 3 months after stem 
cell transplantation. Because of ocular surface damage and 
keratopathy caused by sulfur mustard, corneal 
transplantation is at high risk. Therefore, delaying the 
corneal transplantation will reduce the chance of rejection 
(23, 129). 
◘ 2-4) Management of the bone marrow suppression 
Many experiences have been described in relation to the 
sulfur mustard damages, one of which is the suppression of 
bone marrow(104). Bone marrow damages comprise 
complete reduction of the granulocyte locations and 
degraded changes in megakaryocytes, leading to aplasia. 
Moreover, sulfur mustard deeply affect other cells such as 
lymphocytes, platelets, and red blood cells. Leukopenia and 
neutropenia may result from bone marrow suppression or 
leukocyte dispatch from the blood stream to infection (142). 
Hematopoietic growth factors such as granulocyte colony 
stimulating (G-CSF) and pegylated form of G-CSF (Peg-G-
CSF) have been approved by Food and Drug Administration 
(FDA), protecting the bone marrow from the toxic effects of 
sulfur mustard. Peg-G-CSF has a longer half-life and more 
retained duration of action than G-CSF. Peg-G- CSF 
improved the sulfur mustard-induced neutropenia as fast as 
or faster than G-CSF, but this effect was not completely on 
hold. These two compounds, in addition to reducing the 
duration of induction of neutropenia due to sulfur mustard, 
can reduce antibiotic use in these victims following 
secondary infection, increased survival times, and reduced 
duration of hospitalization for these patients (104, 142). 
◘2-5) Gene therapy 
The development of new treatment strategies, such as 
immunotherapy has been considered to increase the 
effectiveness of treatments by targeting malignant cells 
through various mechanisms(143). Gene therapy has been 
the recent method to treat a numerous range of genetic 
disorders, specially cancers, that occur by the insertion of a 
manipulated gene into the defective cell. This includes two 
main strategies: (1) gene replacement, in fact the delivery of 
a normal gene to the cell, for modifying cell function 
through correcting the functional protein, and (2) gene 
silencing, a process in which an antisense RNA to silence an 
overexpressed gene. This action is performed to suppress the 
transcription in the cells by connecting to a special mRNA 
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location through base pairing in DNA molecules. Delivering 
healthy and effective genes to target cells can be done by 
physical (ultrasound and electroporation), chemical (lipid 
and polymer-based gene vehicles), and biological methods 
(bacteria, viruses, and exosomes) (143-145). These strategies 
can specifically affect tumor cells without an important 
effect on normal cells. Hence, they bring better quality of life 
for the patients. However, gene therapy, cancer vaceiness 
and epigertic agents could not completely prevent relapse of 
complications in some cancers such as squamous cell 
carcinoma, melanoma, lung, prostate and hematopoietic 
malignancies. Table 2 shows factors affecting genetic 
profile, cancer vaccines, epigenetic drugs with dose and 
general side effects(143). 
Table 2. The proposed drugs (genetics, cancer vaccines, epigenetics) in patients exposed to sulfur mustard, which have 
caused a type of cancer with their doses.  
* Genetic therapeutics 
Medicin name The dosage and method of its implementation Author(s) or 
Sources-Year-
Reference(s) 
-Gendiceine It is a dose of 1.0ᵡ1012 viral particle intratumoral injection once a week for eight weeks, 
before or simultaneous radiotherapy 2 Gy per fraction, five fraction a week to a total dose 
of 70 Gy. 
Zhang et al.-
2005,(146) 
Ma et al.-2008,(147) 
Zhang et al.-
2018,(148) 
-Rigvir -After surgery, was administered 2 ml intramuscularly for sequential days. Next, after 4 
weeks, it was repeated for three consecutive days and continual about 1 month later. This 
regimen will be the first year. 
- Then, every 6 weeks during the first half of the second years every 2 months during the 
second half of the second year. 
- Thereafter, every 3 months during the third year. 
Donina et al.-
2015,(149) 
Babiker et al.-2017, 
(150) 
-Oncorine It is a dose of 5ᵡ 1011 -1.5 ᵡ1012 viral particle, intratumoral injection per day for 5 days. 
Treatment repeated every 3 weeks.  
Note: All patients should receive at least 2 courses of chemotherapy. 
Xia et al.-2004, (151) 
-Talimogene 
laherparepvec, or T-vec 
(Imlygic, Amgen) 
It is injected subcutaneously or intralesional so that first dose is 106 plaque forming unit 
(PFU)/ml, then after 3 weeks, 108 plaque forming unit (PFU)/ml every 2 weeks for at least 
six months. 
Andtbacka et al.-
2014, (152) 
FDA-2015, (153) 
* Cancer vaccine 
-Cimavax-Epidermal 
Growth Factor (EGF) 
After 4 to 6 weeks from the end of the first chemotherapy session, it is injected 200µg over 
4 sites intramuscularly (50 micrograms per each deltoid muscle and each gluteus muscle) 
every 2 weeks for 4 doses and then every month 
Cheng & Kananathan-
2012, (154) 
Rodriguez et al.-2016, 
(155) 
-Sipuleucel-T 
(ProvengeTM) 
It is IV infused a minimum of 50 million autologous CD54+ cells activated with Prostatic 
acid phosphatase (PAP) or Granulocyte-macrophage colony-stimulating factor (GM-CSF) 
in 250 ml of lactated Ringer solution , every 2 weeks, for  three doses 
Kantoff et al.-2010, 
(156) 
Anassi & Ndefo-2011, 
(157) 
* Epigenetic therapeutics 
-Azacitidine (VidazaTM) It is injected subcutaneously or intravenously  75 mg /m2  for 7 days, next every month ( 
Based on its effectiveness, it will be adjusted during subsequent doses). 
Kaminskas et al.- 
2005 a, b, (158, 159) 
-Decitabine (DacogenTM) Two regimes are recommended for it: 
Regimen1: It is IV infused 15 mg/m2 tid for 3 days, with intervals of 6 weeks 
Regimen2: It is IV infused 20 mg/m2 daily for 5 days, with interval of 6 weeks 
Rahmani & 
Abdollahi- 2017, 
(143) 
-Vorinostat (ZolinzaTM) -400 mg is given orally once a day, preferably with food.  Mann et al.-2007, 
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-If necessary to reduce toxicity: 300 mg once daily or 300 mg once daily for 5 consecutive 
days per week. Treatment will be continued until disease progression, unacceptable 
toxicity, inefficiency, or dissatisfaction with the patient. 
(160) 
Romidepsin (IstodaxTM) -IV injected 14 mg/m2 over a 4-hour on days 1, 8 and 15 of a 28-day cycle.  
- It is repeated every 28 days if it is helpful and tolerable to the patient. 
- To control undesirable drug reactions, the medication will either be discontinued or 
interrupted with or without reduction to 10 mg / m2. 
FDA-2014, (153) 
-Belinostat (BeleodaqTM) -It is IV infusion of 1000 mg/m2 over 30 minutes once daily on Days 1-5 of a 21-day cycle. 
* Each vial also contains 1000 mg L-Arginine, USP as an inactive ingredient. 
**With 9 ml of sterile water for preparation, then diluted with 250 ml of sodium chloride 
0.9% for intravenous infusion. 
-To control undesirable drug reactions, the medication will either be discontinued or 
interrupted with or without dosage reduction by 25%. 
FDA-2014,(161) 
Lee et al.-2015, (162) 
-Chidamide (EpidazaTM) -It is administered orally 30 or 50 mg twice a week for 2 weeks, followed by 1 week of rest. 
- The total drug is taken at two orders, 120 mg and 200 mg for a 3-week period, 
respectively. 
Shi et al.-2015, (163) 
 
-Panobinostat (FarydakTM) -It is administered orally eight three-week cycles. 
 Each cycle includes; 20 mg, taken orally once every other day for 3 doses per week (on 
Days 1, 3, 5, 8, 10, and 12)  
of weeks 1 and 2 of each 21-day cycle. 
*With regard to the clinical benefits, 8 cycles continue, unless the severity of the disease is 
resolved or significant toxicity occurs. 
**Some sources point out that with this drug, prescribe bortezomib 1. 3 mg / m2 
intravenously and dexamethasone 20 mg orally. 
San-Miguel et al.-
2014, (164) 
FDA-2015,(165) 
Moore-2016, (166) 
 
 
■ Conclusion 
After the synthesis of mustard compounds (e.g. sulfur 
mustard) in the nineteenth century, it has been frequently 
used as incapacitating or death agent in wars in the last 
century, and may be used in war conflicts and terrorist 
attacks in the near future or not far away. Sulfur mustard is a 
toxic agent with severe effects on various systems of human 
body. Sulfur mustard with a number of pathogenic 
mechanisms referred to with certainty, such as DNA 
alkylation, NAD depletion, inactivation of glutathione, and 
leading to loss of preservation against oxidant stress, e.g., 
GSH depletion, increase in cellular ROS level, causing 
damage to various organs of the body. Different systems in 
the human body are affected by this chemical warfare, but 
skin, respiratory, and eyes are the main systems undergoing 
the provocative effects of sulfur mustard. When rapidly 
absorbed by human body, it quickly damages the cell 
proliferation in the bone marrow, and severely suppress the 
immune system. Their effects will appear several minutes to 
weeks even years. The patients and their countries involved 
will have many economic, social, psychological problems,  
 
and medical costs for long period of time. Therefore, authors  
of this paper wish that international organizations such as the 
organization for prohibition of chemical weapons (OPCW), 
the United Nations (UN), the World Health Organization 
(WHO), the Red Cross and the red crescent, and any 
international organizations related this point, also Non-
Government Organization (NGO), not only approved the 
prohibition of the use of chemical weapons, but also in 
practice and deal with any country that uses these chemical 
weapons. It is hoped that in the near future, we will see the 
demolition of all destructive weapons globally, and that the 
slogan of peace, friendship and kindness to each other, bring 
out the best in us, because there may not be tomorrow for 
anyone of us.   
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